Neuraxpharm announces closing of acquisition of established products from Sanofi

Neuraxpharm announces closing of acquisition of established products from Sanofi

Düsseldorf and Barcelona – February 1, 2023 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the closing of the previously announced acquisition of two established product portfolios for CNS disorders, pain and vascular diseases from Sanofi.

The well-established products that Neuraxpharm has acquired include 15 products addressing CNS disorders and two products in pain and vascular diseases. Combined, both portfolios include 17 molecules representing 38 brands that are marketed globally in more than 50 countries for the benefit of patients across a large spectrum of diseases. These global brands further solidify Neuraxpharm’s position as a leading CNS pharmaceutical company in Europe and increase the company’s global footprint and business.

Dr. Jörg-Thomas Dierks, Chief Executive Officer of Neuraxpharm, said: “These newly acquired products not only strengthen our presence as a leading European specialty pharmaceutical company focused on CNS, but also lay the ground for further expansion of our international presence.”